Category
Cancer
Sub Category
Lymphoma
Study Name
CC-5013-NHL-008: A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. The "MAGNIFY" Trial
Principal Investigator
Gordan Srkalovic, MD
Study Information
Contact for Questions
Neelam Singh, PhD: 517-364-5591

Site view: at a glance